Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04978428

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

Obsessive-Compulsive Disorder Clinical Trial

Official title:
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study

Clinical Trial Summary

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

Clinical Trial Description

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). OCRDs include obsessive compulsive disorder (OCD), trichotillomania, skin picking, tourettes disorder, and hoarding disorders. These disorders appear linked in terms of phenomenology and possibly biology. Fifteen subjects with OCRDs will be treated in an open-label fashion with Epidiolex (2.5 mg/kg twice daily for one week followed by 5mg/kg twice daily) for two total weeks of active treatment. The hypothesis to be tested is that Epidiolex will result in reduction in symptoms of OCRDs (improvement in symptoms will be indicated by lower scores on established outcome measures of OCRDs symptoms that have been used in prior studies). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04978428
Study type Interventional
Source University of Chicago
Contact Eve K Chesivoir, BA
Phone 7737029066
Email chesivoir@yoda.bsd.uchicago.edu
Status Recruiting
Phase Phase 2
Start date April 14, 2022
Completion date September 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3